[ASMB] Assembly Biosciences, Inc.


Type of security: Stock

Sector: Health Care

Industry: Major Pharmaceuticals

Market Capitalization: 100.97 M

Exchange: NASDAQ

The data is delayed by 15 minutes.


Price: 11.78 Change: 0.03 (0.26%)
Ext. hours: Change: 0 (0%)

chart ASMB

Refresh chart

Strongest Trends Summary For ASMB

ASMB is in the long-term down -62% below S&P in 1 year and up 145% in 4 years.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart


Description: Assembly Biosciences, Inc. provides development and commercialization of gastrointestinal products in the United States. The company is developing two late-stage development product candidates, including VEN 307, a diltiazem cream for the relief of pain associated with anal fissures; and VEN 308, a phenylephrine gel for the treatment of fecal incontinence associated with ileal pouch anal anastomosis. It is also involved in the development of VEN 310 as a colonic delivery mechanism, which is a PH sensitive system to deliver bacteria, complex proteins, viral antigens, small molecules, and other treatments. The company was formerly known as Ventrus Biosciences Inc. and changed its name to Assembly Biosciences, Inc. in July, 2014. Assembly Biosciences, Inc. was founded in 2005 and is based in New York, New York.

See how to gain 20% in 14 sec with TrendsInvesting

Fundamental Ratios
Shares Outstanding17.23 M EPS-2.74 EPS Growth - 4 Quarters EPS Growth - Q/Q
EPS Growth - Y/Y Sales Growth - 4 Quarters Sales Growth - Q/Q P/E-7.94
P/E To EPS Growth P/S P/BV0.81 Price/Cash Per Share
Price/Free Cash Flow-6.68 ROA-19.42% ROE-21.56% ROI
Current Ratio45.27 Quick Ratio Long Term Debt/Equity Debt Ratio0.02
Gross Margin Operating Margin Net Profit Margin Dividend Payout Ratio
Dividend Yield
Fundamental Data
Cash From Financing Activities70.67 M Cash From Investing Activities-30 K Cash From Operating Activities-3.67 M Gross Profit
Net Profit-7.14 M Operating Profit-7.2 M Total Assets138.35 M Total Current Assets96.34 M
Total Current Liabilities2.13 M Total Debt Total Liabilities13.73 M Total Revenue
Technical Data
High 52 week64.16 Low 52 week19.05 Last close21.65 Last change1.36%
RSI48.37 Average true range1.27 Beta0.86 Volume30.34 K
Simple moving average 20 days-2.81% Simple moving average 50 days-0.93% Simple moving average 200 days-32.17%
Performance Data
Performance Week-5.38% Performance Month3.49% Performance Quart-11.12% Performance Half-40.98%
Performance Year-61.19% Performance Year-to-date-4.29% Volatility daily3.21% Volatility weekly7.17%
Volatility monthly14.69% Volatility yearly50.89% Relative Volume234.77% Average Volume179.16 K
New High New Low


2019-03-13 07:05:00 | Assembly Biosciences to Participate in the Jefferies 2019 HBV Summit

2019-03-06 13:35:11 | If You Had Bought Assembly Biosciences Stock Three Years Ago, You Could Pocket A 261% Gain Today

2019-02-28 17:00:00 | Assembly Biosciences Reports Fourth Quarter and Year End 2018 Financial Results

2019-02-19 17:47:10 | Generic-Drugs Outlook: Price Erosion to Hurt Near-Term Prospects

2019-02-13 08:25:00 | Market Trends Toward New Normal in Brighthouse Financial, BioMarin Pharmaceutical, EZCORP, Assembly Biosciences, A-Mark Precious Metals, and American Public Education — Emerging Consolidated Expectations, Analyst Ratings

2019-01-31 09:30:02 | Mylan MYL Jumps: Stock Rises 7.1%

2019-01-15 12:24:55 | Assembly Biosciences, Inc. NASDAQ:ASMB Insiders Increased Their Holdings

2019-01-07 07:00:00 | Assembly Biosciences Announces Completion of Enrollment in Two Phase 2a Studies with ABI-H0731 for Chronic Hepatitis B Virus

2018-12-16 09:04:00 | Here is What Hedge Funds Think About Assembly Biosciences Inc ASMB

2018-12-03 08:52:01 | Amphastar Pharmaceuticals AMPH Catches Eye: Stock Jumps 6.7%

2018-11-30 08:17:09 | Should You Worry About Assembly Biosciences Inc’s NASDAQ:ASMB CEO Pay?

2018-11-12 07:05:00 | Assembly Biosciences Presents Final Results of Phase 1b Study of ABI-H0731 at 2018 AASLD

2018-11-08 11:10:04 | Assembly Biosciences ASMB Reports Q3 Loss, Tops Revenue Estimates

2018-11-08 10:04:31 | Assembly Biosciences: 3Q Earnings Snapshot

2018-11-08 07:00:00 | Assembly Biosciences Announces Third Quarter 2018 Financial Results and Provides HBV Program Update

2018-10-31 10:32:02 | Analysts Estimate Assembly Biosciences ASMB to Report a Decline in Earnings: What to Look Out for

2018-10-31 07:00:00 | Assembly Biosciences Announces November Conference Participation

2018-10-16 07:36:37 | Report: Developing Opportunities within The Ensign Group, Forterra, Inc., Audentes Therapeutics, Assembly Biosciences, Capital Senior Living, and Myomo — Future Expectations, Projections Moving into 2018

2018-10-08 15:16:30 | Recent Assembly Biosciences Weakness Provides Attractive Entry Point, B Riley FBR Says In Upgrade

2018-10-02 07:05:00 | Assembly Biosciences Announces Oral Presentation at 2018 AASLD

2018-10-01 08:43:56 | Shareholders Should Check The Ownership Structure Of Assembly Biosciences Inc NASDAQ:ASMB

2018-08-28 07:05:00 | Assembly Biosciences to Present at Upcoming Investor Conferences

2018-08-16 07:35:00 | Analysis: Positioning to Benefit within Amtech, NL Industries, Dova Pharmaceuticals, Sientra, Dorian LPG, and Assembly Biosciences — Research Highlights Growth, Revenue, and Consolidated Results

2018-08-08 20:25:12 | Assembly Biosciences ASMB Reports Q2 Loss, Misses Revenue Estimates

2018-08-08 19:19:28 | Assembly Biosciences: 2Q Earnings Snapshot

2018-08-08 16:05:00 | Assembly Biosciences Announces Second Quarter 2018 Financial Results

2018-07-25 07:05:00 | Assembly Biosciences Announces FDA Fast Track Designation Granted to ABI-H0731 for the Treatment of Hepatitis B Virus Infection

2018-07-16 16:05:00 | Assembly Biosciences Announces the Closing of its Offering of Common Stock and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

2018-07-11 19:29:11 | Assembly Biosciences Announces Pricing of $144 Million Offering of Common Stock

2018-07-10 16:01:00 | Assembly Biosciences Announces Proposed Underwritten Offering of Common Stock

2018-07-09 07:05:00 | Assembly Biosciences Initiates Two Phase 2a Trials of ABI-H0731 for the Treatment of Hepatitis B Virus Infection

2018-06-13 07:05:00 | Assembly Biosciences to Host Research and Development Day on Wednesday, June 20, 2018

2018-06-08 07:05:00 | Assembly Biosciences Announces Inducement Grants Under NASDAQ Listing Rule 5635c4

2018-06-04 07:00:00 | Assembly Biosciences to Participate in Jefferies 2018 Global Healthcare Conference

2018-05-29 08:10:00 | Factors of Influence in 2018, Key Indicators and Opportunity within Assembly Biosciences, MGP Ingredients, Globant S.A, 8point3 Energy Partners LP, Flexion Therapeutics, and Enanta Pharmaceuticals — New Research Emphasizes Economic Growth

2018-05-07 17:57:28 | Assembly Biosciences: 1Q Earnings Snapshot

2018-05-07 16:05:00 | Assembly Biosciences Announces First Quarter 2018 Financial Results

2018-04-13 10:31:16 | Chardan: Assembly Biosciences Hep B Antiviral Data 'Positive,' But Undifferentiated From Competitor Johnson & Johnson

2018-04-12 07:59:28 | Was Assembly Biosciences Inc’s NASDAQ:ASMB Earnings Growth Better Than The Industry’s?

2018-04-12 03:10:00 | Assembly Biosciences Presents Positive Interim Data from Phase 1a and 1b Studies of ABI-H0731 in HBV Patients in a Late-Breaker Session at the EASL Conference

2018-04-10 17:40:00 | Assembly Biosciences to Host Conference Call on April 12 to Review ABI-H0731 Interim Phase 1b Data in HBV Patients Featured in Late-Breaker Poster at EASL

2018-04-04 08:00:00 | Report: Developing Opportunities within Assembly Biosciences, Guaranty, Noble Midstream Partners LP, Lithia Motors, Vectrus, and Kforce — Future Expectations, Projections Moving into 2018

2018-04-02 16:54:24 | Assembly Biosciences Appoints Jackie Papkoff, PhD, Senior Vice President, Chief Scientific Officer Microbiome

2018-04-02 07:30:00 | Blog Exposure - Assembly Biosciences to Present ABI-H0731 Phase-1b Interim Data at The International Liver CongressTM

2018-03-28 05:30:00 | Assembly Biosciences Announces ABI-H0731 Phase 1b Interim Data Accepted as a Late-Breaker Poster at The International Liver Congress™ EASL

2018-03-12 07:05:00 | Assembly Biosciences Announces Additions to Management Team and Board of Directors

2018-03-05 07:00:00 | Assembly Biosciences to Present at Cowen’s 38th Annual Healthcare Conference

2018-02-06 08:00:00 | Investor Expectations to Drive Momentum within Regal Beloit, Kaiser Aluminum, AngioDynamics, Mulesoft, Assembly Biosciences, and Woodward — Discovering Underlying Factors of Influence

2018-02-05 07:05:00 | Assembly Biosciences to Participate in Leerink Partners 7th Annual Global Healthcare Conference

2018-02-02 16:30:00 | Assembly Biosciences Reports Inducement Grants under NASDAQ Listing Rule 5635c4